



F. No. 04-14/2023-QC  
Government of Pakistan  
**Drug Regulatory Authority of Pakistan**  
Ministry of National Health Services,  
Regulation & Coordination  
\*\*\*\*\*


Islamabad, the 03<sup>rd</sup> November, 2023.

**TERMINATION OF DRUG PRODUCT RECALL**

M/s. Roche Pakistan Ltd.,  
1st Floor, 37-B, Block 6. P.E.C.H.S,  
**Karachi.**

Subject: **CASES OF LOSS OF VISION DUE TO OFF-LABEL USE OF AVASTIN INJECTION IN PUNJAB.**

1. Reference is made to subject cited "Drug Product Recall" of even No. of this division dated 25-09-2023 wherein it was directed to recall the suspected batches of subject mentioned product i.e., Batch No. H0352B11, B7266B20 and B7266B07.
2. Samples of above-mentioned batches were sent to Central Drugs Laboratory (CDL) Karachi for the purpose test/analysis to verify the quality and safety of suspected product. CDL, Karachi vide report No. KQ-9-23-000115.(Final) and No. KQ-9-23-000116.(Final) dated 10-10-2023 (**Reports annexed**) has declared the samples of above-mentioned batches as of standard quality.
3. Therefore, keeping in view the reports of CDL, above-mentioned Drug Product Recall is hereby terminated with the approval of competent authority i.e. the Director, QA&LT Division, DRAP, Islamabad.

  
**(Hafiz Sanaullah Babar)**  
Deputy Director (QA&LT)  
DRAP, Islamabad.

Copy to:

- i. PS to CEO, DRAP, Islamabad.
- ii. Additional Director/Office In-charge DRAP Lahore, Karachi, Islamabad, Peshawar & Quetta.
- iii. Chief Drugs Controller/Inspector Punjab, Sind, Khyber Pakhtunkhwa, Balochistan, ICT, Gilgit-Baltistan & Azad Jammu & Kashmir.
- iv. Office Copy.